

November 12, 2018

Scrip Code: 500124

Corporate Relationship Department BSE Limited Dalal Street, Fort <u>Mumbai – 400 001</u> Fax Nos.: 022-22723121 / 22723719 Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India.

CIN: L85195TG1984PLC004507

Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com

National Stock Exchange of India Ltd. "Exchange Plaza" Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 Fax Nos.: 022-26598120/ 26598237

## Scrip Code: DRREDDY-EQ

Dear Sirs,

## **Sub: Intimation**

This is to inform you that on 9<sup>th</sup> November 2018, the Regulatory Authority of Germany (Regierung von Oberbayern) concluded the follow-on audit of our Formulations manufacturing facility in Duvvada, Vishakapatnam. The facility is considered compliant and the EU-GMP certification continues to remain active with one specific exclusion of a new product. The Company will be submitting a detailed Corrective and Preventive Action Plan (CAPA) to the authorities.

This is for your information and record.

With regards,

Sandeep Poddar

Company Secretary

Encl: As above

CC:- New York Stock Exchange Inc.(Stock Code :RDY)